Rosuvastatin: The Most Efficient Treatment Option For Patients With Dyslipidemia

Bibliography

• Neaton JD, Blackburn H, Jacobs D et al.: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 152(7), 1490–1500 (1992).
   Google Scholar
• Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of followup from the Framingham study. JAMA 257(16), 2176–2180 (1987).
   Google Scholar
• Jousilahti P, Vartiainen E, Tuomilehto J: Effect of risk factors and changes in risk factors on coronary mortality in three cohorts of middle-aged people in eastern Finland. Am. J. Epidemiol. 141(1), 50–60 (1995).
   Google Scholar
• Assmann G, Schulte H: Relation of highdensity lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am. J. Cardiol. 70, 733–737 (1992).
   Google Scholar
• Keys A: Coronary heart disease in seven countries. Circulation 41 (Suppl. 1), 1–211 (1970).
   Google Scholar
• Ahmed SM, Clasen ME, Donnelly JE. Management of dyslipidemia in adults. Am. Fam. Physician. 57(9), 2192–2204, 2207–2208 (1998).
   Google Scholar
• Hjermann I, Velve Byre K, Holme I, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 2(8259), 1303–1310 (1981).
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251(3), 365–374 (1984).
   Google Scholar
• Manninen V, Tenkanen L, Koskinen P, et al: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85, 37–45 (1992).
   Google Scholar
• Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279, 1615–1622 (1998).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N. Engl. J. Med. 335, 1001–1009 (1996).
   Google Scholar
• The long-term intervention with pravastatin in ischaemic disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the long-term intervention with pravastatin in ischaemic disease (LIPID) study. N. Engl. J. Med. 339, 1349–1357 (1998).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
   Google Scholar
• Confirms the randomized trials that statin therapy reduces coronary events in proportion to the low-density lipoprotein cholesterol reduction irrespective of lipid profile or presenting characteristics.
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al.: Comparison of intensive and moderate lipid lowering with statins after coronary syndromes. N. Engl. J. Med. 350(15), 1495–1504 (2004).
   Google Scholar
• Indicates that acute coronary syndrome patients benefit from intensive LDL-C lowering.
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).
   Google Scholar
• Indicates that intensive lipid-lowering provides additional benefits in coronary heart disease patients.
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9), 1071–1080 (2004).
   Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124(Suppl.), S11–S20 (1996).
   Google Scholar
• Colquhoun D, Keech A, Hunt D et al.: Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur. Heart. J. 25(9), 771–777 (2004).
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8–15 (1989).
   Google Scholar
• DeBacker G, Ambrosioni E, Borch-Johsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart. J. 24, 1601–1610 (2003).
   Google Scholar
• National Cholesterol Education Program: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment III). JAMA 285, 2486–2497 (2001).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CNB et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   Google Scholar
• Wood D, De Backer G, Faergeman O, Graham I, Mancia G and Pyörälä, K: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. 19(10), 1434–503 (1998)
   Google Scholar
• Sueta CA, Chowdhury M, Boccuzzi S et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 83, 1303–1307 (1999).
   Google Scholar
• EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357, 995–1001 (2001).
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid- lowering therapy and achieving lowdensity lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459–467 (2000).
   Google Scholar
• Crouse JR, Simpson RJ Jr, Weiss TW, Markson LE, Alexander CM: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol. 92, 79–81 (2003).
   Google Scholar
• McTaggart F, Buckett L, Davidson R et al.: Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 87 (5A), 28B–32B (2001).
   Google Scholar
• Details the pharmacology of rosuvastatin.
   Google Scholar
• Roach A, Tsikouris JP, Haase KK: A new HMG-CoA reductase inhibitor for hypercholesterolemia. Formulary 37, 179–185 (2002).
   Google Scholar
• Chapman MJ, McTaggart F: Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler. Suppl. 2(4), 33–36 (2002)
   Google Scholar
• Buckett L, Ballard P, Davidson R et al.: Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atheroscler. Suppl. 151, 41 (2000).
   Google Scholar
• Martin PD, Mitchell PD, Schneck DW: Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. 54(5), 472–477 (2002).
   Google Scholar
• Martin PD, Warwick MJ, Dane AL, Brindley C, Short T: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin. Ther. 25, 2553–2563 (2003).
   Google Scholar
• Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ: No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 42(10), 1116–1121 (2002).
   Google Scholar
• Simonson SG, Martin PD, Mitchell PD, Schneck DW, Lasseter KC, Warwick MJ: Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects. Eur. J. Clin. Pharmacol. 58, 669–675 (2003).
   Google Scholar
• Lee E, Ryan S, Birmingham B et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78(4), 330–341 (2005).
   Google Scholar
• Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT: Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein cholesterol: a multinational, multicenter, double-blind study. J. Formos. Med. Assoc. 101, 478–487 (2002).
   Google Scholar
• Schuster H: The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev. Cardiovasc. Ther. 5(2), 177–192 (2007).
   Google Scholar
• Details rosuvastatin studies on cardiovascular risk reduction and patient outcomes.
   Google Scholar
• Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am. J. Cardiol. 91(Suppl), 3C–10C (2003).
   Google Scholar
• Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on lowdensity lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. 88, 504–508 (2001).
   Google Scholar
• Jones PH, Davidson MH, Stein EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR). Am. J. Cardiol. 93, 152–160 (2003).
   Google Scholar
• Largest study to directly compare the efficacy of rosuvastatin with atorvastatin, simvastatin and pravastatin; demonstrated that rosuvastatin reduced LDL-C more than other statins.
   Google Scholar
• Clearfield M, Kallend D, Palmer M: Efficacy and safety of rosuvastatin 10 mg versus atorvastatin 20 mg: results of the PULSAR study. Atherosclerosis. 6(1), 104, Abs W16-P-014 (2005).
   Google Scholar
• Leiter LA, Palmer M, Sosef F for the POLARIS study investigators: Efficacy of rosuvastatin 40 mg versus atorvastatin 80 mg in patients with the metabolic syndrome: results from a subgroup of the POLARIS study. 41st EASD Annual Meeting, Athens, 10–15 September, A1085 (2005).
   Google Scholar
• Shepherd J, Hunninghake DB, Barter P, Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am. J. Cardiol. 91(Suppl 5A), 11C–9C (2003).
   Google Scholar
• Schuster H, Barter PJ, Stender S et al.: Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am. Heart. J. 147, 705–712 (2004).
   Google Scholar
• Demonstrates that more patients on rosuvastatin reached LDL-C goals than patients on other statins.
   Google Scholar
• Davidson M, Ma P, Stein EA et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89, 268–275 (2002).
   Google Scholar
• Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomized, double-blind study. J. Cardiovasc. Risk. 8, 383–390 (2001).
   Google Scholar
• McKenney JM: Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am. J. Health. Syst. Pharm. 62(10), 1033–1047 (2005).
   Google Scholar
• Stein E, Strutt KL, Miller E, Southworth H: Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolamia. Am. J. Cardiol. 92, 1287–1293 (2003).
   Google Scholar
• Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG: Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 91, 33–41 (2003).
   Google Scholar
• Hunninghake DB, Stein EA, Bays HE et al.: Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron. Artery. Dis. 15, 115–123 (2004).
   Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C et al.: A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur. Heart. J. 26(24), 2664–2672 (2005).
   Google Scholar
• Demonstrates the benefits of rosuvastatin compared with atorvastatin in metabolic syndrome patients.
   Google Scholar
• Berne C, Siewert-Delle A, URANUS study investigators: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with Type 2 diabetes mellitus: results from the URANUS study. Cardiovasc. Diabetol. 4, 7 (2005).
   Google Scholar
• Demonstrates the benefits of rosuvastatin compared with atorvastatin in Type 2 diabetes.
   Google Scholar
• Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group: Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with Type 2 diabetes – CORALL study. J. Intern. Med. 257, 531–539 (2005).
   Google Scholar
• Demonstrates the benefits of rosuvastatin compared with atorvastatin in Type 2 diabetes.
   Google Scholar
• Kritharides L: Reducing low-density lipoprotein cholesterol – treating to target and meeting new European goals. Eur. Heart. J. 6 (Suppl. A), A12–A18 (2004).
   Google Scholar
• Post-hoc analysis of the Measuring Effective Reductions in Cholesterol Using Rosvastatin therapY (MERCURY) I trial indicating the ability of rosuvastatin to meet 2003 European guideline goals
   Google Scholar
• Schuster H, Barter PJ, Stender S et al. Effects of rosuvastatin and atorvastatin on plasma lipids in Type 2 diabetes patients in the MERCURY I study. Diabetologia 47(Suppl. I), A409 Abs 1146 (2004); poster presented at EASD (2004).
   Google Scholar
• The FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
   Google Scholar
• Fenofibrate did not significantly reduce coronary events in Type 2 diabetes patients.
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685–696 (2004).
   Google Scholar
• Statin therapy reduced cardiovascular events in Type 2 diabetes patients.
   Google Scholar
• Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zinderman AH: LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr. Med. Res. Opin . 21(11), 1865–1874 (2005).
   Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358(9298), 2026–2033 (2001).
   Google Scholar
• Frost PH, Havel RJ:. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am. J. Cardiol. 81(4A), 26B–31B (1998).
   Google Scholar
• Jones PH, Hunninghake DB, Ferdinand KC et al.: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther. 26(9), 1388–1399 (2004).
   Google Scholar
• Rader DJ, Davidson MH, Caplan RJ, Pears JS: Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am. J. Cardiol. 91(5A), 20C-23C (2003).
   Google Scholar
• Betteridge D, Gibson M: Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with Type 2 diabetes; results of the ANDROMEDA study. Atheroscler. Suppl. 5, 107 Abs M464 (2004).
   Google Scholar
• The DECODE Study Group; Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 49, 2837–2846 (2006).
   Google Scholar
• Deedwania PC, Hunninghake DB, Bays HE et al.: Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am. J. Cardiol. 95(3), 360–366 (2005).
   Google Scholar
• Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group: Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes. Obes. Metab. 7(4), 430–438 (2005).
   Google Scholar
• Ballantyne CM, Weiss R, Moccetti T et al.: EXPLORER Study Investigators: Efficacy and safety of rosuvastatin 40 mg alone or in combination with exetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am. J. Cardiol. 99, 673–680 (2007).
   Google Scholar
• Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K: Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia. Diabetes. Res. Clin. Pract. 64, 137–151 (2004).
   Google Scholar
• Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD: Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidaemia and low-high density lipoprotein cholesterol levels. Am. J. Cardiol. 91, 1304–1310 (2003).
   Google Scholar
• Ballantyne C, Sosef F, Duffield E: Efficacy and safety of rosuvastatin plus ezetimibe in high-risk patients: Results from the EXPLORER Study. Atherosclerosis 7(Suppl.), 552 Abs Th-P16: 270 (2006).
   Google Scholar
• Stein EA, Harris S, schleman M, Sager PT: Ezetimibe added to rosuvastatin for severely hypercholesterolemic patients: effects on lipid measures and C-reactive protein. Atheroscler. 6(Suppl.), 99 Abs W16-O-003 (2005).
   Google Scholar
• Ose L, Tonstad S, Harris S, Marotti M: Ezetimibe added to rosuvastatin for severely hypercholesterolemic patients: effects on lipid measures and C-reactive protein. Atheroscler. 6(Suppl.), 117 Abs W16-P-06 (2005).
   Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators: Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556–65 (2006).
   Google Scholar
• Ridker PM, JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108(19), 2292–2297 (2003).
   Google Scholar
• Brewer HB: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 92(Suppl.), 23K–29K (2003).
   Google Scholar
• Shepherd J, Hunninghake DB, Stein EA et al.: Safety of rosuvastatin. Am. J. Cardiol. 94, 882–888 (2004).
   Google Scholar
• Pooled safety data indicate that the safety profile of rosuvastatin is similar to other marketed statins.
   Google Scholar
• Grundy SM: The issue of statin safety: where do we stand? Circulation. 111(23), 3016–3019 (2005).
   Google Scholar
• Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 102, 52–60 (2004).
   Google Scholar
• Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF: Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am. J. Cardiol. 96(9), 1290–2 (2005).
   Google Scholar
• Vidt D, Harris S, McTaggart F, Ditmarsch M, Sager P, Sorof J: Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am. J Cardiol. 97, 1602–1606 (2006).
   Google Scholar
• Stein E, Melezinkova H, LeMaulf F et al.: Efficacy and safety of rosuvastatin 40mg in patients with severe Type IIa and IIb hypercholesterolaemia. Atheroscl. Suppl. 6(1), 99 Abs W16-O-033 (2005).
   Google Scholar
• Sorof J, Berne C, Siewert-Delle A et al.: Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in Type 2 diabetic patients. Diabetes Res. Clin. Prac. 72, 81–7 (2006).
   Google Scholar
• Kasliwal RK, Wilson L, Shakir S: Safety profile of rosuvastatin as used in general practice in England: a prescription-event monitoring study. Circulation 113(8), e331 Abs P101 (2006).
   Google Scholar
• McAfee AT, Ming EE, Seeger JD et al: The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol. Drug Saf. (2007) (Epub ahead of print).
   Google Scholar
• Goettsch WG, Heintjes EM, Kastelein JJP, et al: Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol. Drug Saf. (2007) (Epub ahead of print).
   Google Scholar
• Report of the National Lipid Association’s Statin Safety Task Force. Am. J. Cardiol. 97(8) (Suppl. 1), S1–S98 (2006).
   Google Scholar
• Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW: The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol. 59, 51–6 (2003).
   Google Scholar
• Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV: Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 73, 322–329 (2003).
   Google Scholar
• Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW: Lack of efficacy of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br. J. Clin. Pharmacol. 55, 94–99 (2003).
   Google Scholar
• Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV: The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol. 58, 527–531 (2002).
   Google Scholar
• Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW: No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1352–1357 (2002).
   Google Scholar
• Martin PD, Dane AL, Schneck DW, Warwick MJ: An open-label, randomized, three-way crossover trial of the effects of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Ther. 25, 459–471 (2003).
   Google Scholar
• Schneck D, Birmingham BK, Zalikowski JA et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75, 455–463 (2004).
   Google Scholar
• Simonson S, Raza A, Martin PD et al.: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76(2), 167–177 (2004).
   Google Scholar
• Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW: Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J. Clin. Pharmacol. 45, 927–934 (2005).
   Google Scholar